TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).

This is an important study using a combination of optogenetics and calcium imaging to provide insight into the function of the cholinergic input to the prelimbic cortex in probabilistic spatial ...

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmac ...

Company to host a webcasttoday at 8:30 a.m. Eastern TimeNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...

Catheter-related bladder discomfort (CRBD), a regrettable consequence post-surgery, manifests as a compelling urge to urinate ...

Neurocrine’s Crenessity approval for CAH treatment represents a transformative opportunity. See why I maintain my strong buy ...

At present no definitive medical treatment exists for acute pancreatitis. [9,10] Pirenzepine has shown encouraging positive responses and a low incidence of adverse effects when used to treat ...

Cobenfy, a drug targeting muscarinic receptors and therefore - at least directly – having a differentiated mechanism of action, has been approved in September 2024, less than a year later.

Researchers from Maplight Therapeutics Inc. presented preclinical data for the investigational muscarinic M1/M4 receptor agonist ML-007, being evaluated for the treatment of neuropsychiatric disorders ...

Diverging from the traditional dopamine-based therapies, Cobenfy is said to address the critical gaps in the current treatments by targeting muscarinic acetylcholine receptors. Its success can ...